Wechselwirkungen · Sarclisa
Sarclisa 1 400 mg solution for injection · Abschnitt 4.5 · PDF-Seite 44
HOS-143565 · Präparat HOS-099018
Because CD38 protein is expressed on the surface of red blood cells, isatuximab, an anti-CD38 antibody, may interfere with blood bank serologic tests with potential false positive reactions in indirect antiglobulin tests (indirect Coombs tests), antibody detection (screening) tests, antibody identification panels, and antihuman globulin (AHG) crossmatches in patients treated with isatuximab (see section 4.4). This interference may persist for at least 6 months after the last administration of isatuximab. The interference mitigation methods include treating reagent RBCs with dithiothreitol (DTT) to disrupt isatuximab binding or other locally validated methods. Since the Kell Blood group system is also sensitive to DTT treatment, Kell-negative units should be supplied after ruling out or identifying alloantibodies using DTT-treated RBCs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-07T16:11:00Z · SHA-256 34012f35e3184222887e1d307474da91513d213995d8abe78e6f866a782cdd2e · Passage ec2cceb15d9d1f8f4bb666f09c702d186c0e2268ee1bc242031a55b4615bd9b7 · Zeichen 268–1115 im Abschnitt